"There are 10,000 hospitals for rich people in China. $50,000 per system, with a 20% reduction = $40,000 multiplied x10,000 = $400m revenue in China alone. Without the implementation of VMS 3+ in pets, which is also a very attractive market. Without calculating one single system in the US and Europe. $400m = CAD 5/share! The company has no debt, sufficient cash and is FDA/EMA/China approved. It is a blockbuster and will replace MRI for heart monitoring and possible other organs as well in all hospitals, because it is cheaper, delivers results much faster (within 10minutes instead of days) and is non-invasive (it is scary to lie down without moving in a "tunnel" that constantly makes noise for 20-30 minutes).
Besides all this Ventripoint can be considered as an AI and COVID19 play."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.